Cure My Disease

Don't miss your cure!

 Log in / Sign up

DNA clues may reveal which esophageal cancers will return soon after surgery

NCT ID NCT06476067

Knowledge-focused Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at whether changes in DNA methylation—a type of epigenetic marker—can help predict if esophageal cancer will come back soon after surgery. Researchers will analyze tumor tissue from 150 patients who had their cancer removed and track who experiences a recurrence within two years. The goal is to develop a biomarker that flags high-risk patients earlier, potentially guiding closer monitoring or additional treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a blood or tissue test that helps doctors identify patients at high risk of early cancer return after surgery.
What could go wrong
This is an observational study, not a treatment trial. The findings may not translate into a reliable clinical test, and the sample size is modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2006

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who had undergone complete esophagectomy.

Ages

20 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who had histologically confirmed ESCC. 2. Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery. 3. Patients for whom tissue samples are available 4. Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery. 5. Written informed consent following full study information is provided to the patient. Exclusion Criteria: 1. Patients lacking clinical information within 2 years of surgery. 2. Patients with multiple cancers.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DNA methylation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DNA methylation Esophageal cancer Recurrence

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nagoya University

    RECRUITING

    Nagoya, Aichi-ken, 4668560, Japan

  • Yamanashi Universiy

    RECRUITING

    Chūō, Yamanashi, 4093898, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.